RESUMEN
BACKGROUND: Interferon has an important role in treatment of viral hepatitis, multiple sclerosis and solid and non-solid tumours. Ischaemia and necrosis of the extremities are relatively little-known adverse effects of treatment with interferon. CASE DESCRIPTION: A 44-year-old woman was treated with interferon-beta for relapsing-remitting multiple sclerosis. She developed ischaemia and necrosis of the right lower extremity. Extensive laboratory and imaging investigations offered no clear diagnosis, leading to suspicion of a connexion with interferon-beta treatment. Discontinuation of interferon lead to rapid healing, clearly suggesting a relationship between interferon and the vascular complications. CONCLUSION: Vascular complications during treatment with interferon seem to arise fairly frequently, and can even occur many years after commencing therapy. When vascular symptoms similar to Raynaud's syndrome develop, careful monitoring of the disease course and treatment with vasodilators if required is important. If this is insufficiently effective, interferon should be discontinued. Prompt recognition can prevent significant morbidity in these patients.
Asunto(s)
Interferón beta/efectos adversos , Interferones/efectos adversos , Necrosis/inducido químicamente , Dedos del Pie , Adulto , Antivirales , Femenino , Humanos , Interferón beta/uso terapéutico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológicoAsunto(s)
Arterias , Hemofilia A/etiología , Trombosis/etiología , Vasculitis/complicaciones , Hemofilia A/complicaciones , Hemofilia A/diagnóstico , Hemofilia A/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Imagen Multimodal , Tomografía de Emisión de Positrones , Trombosis/complicaciones , Trombosis/tratamiento farmacológico , Tomografía Computarizada por Rayos XRESUMEN
Long-term complete remission in IgD multiple myeloma (MM) is rare. This case report describes a patient with a stage IIIB IgD-MM, who was treated with conventional melphalan and prednisone chemotherapy. The monoclonal protein disappeared after four cycles and therapy was discontinued after 14 cycles. Re-evaluation after a follow up of more than 8 years demonstrates a continuing complete remission suggesting a cure. This is remarkable, considering that several adverse prognostic factors were present. In addition a concise review on IgD-MM is given.